Atlas Trials

A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Clinical trial NCT02735876 · WITHDRAWN

Trial details

NCT number
NCT02735876
Sponsor
Acerta Pharma BV
Status
WITHDRAWN
Phase
Phase 3
Study type
INTERVENTIONAL
Mantle Cell Lymphoma
Start date
2016-05-01
Primary completion
2020-06-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.